Funded Biotechnology Startups in Berkeley
Across the 21 Berkeley biotech entries shown, the largest disclosed round is Carmot Therapeutics’ $150M (2023-05-25), and it meaningfully stands above the…
Across the 21 Berkeley biotech entries shown, the largest disclosed round is Carmot Therapeutics’ $150M (2023-05-25), and it meaningfully stands above the next-largest disclosed amounts of $125M (Caribou Biosciences on 2023-07-13) and $90M (Perfect Day on 2024-01-05). The list also concentrates in a clustered time window: 7 rounds fall between 2023-02-15 (Flightpath Biosciences) and 2023-10-18 (Actym Therapeutics), versus fewer entries elsewhere.
Stage labeling is mixed, with five entries marked “Series Unknown” (including Kyverna Therapeutics at $25M on 2025-11-03, SonALAsense at $46M on 2024-12-12, and BioGlyph as undisclosed on 2024-08-06) and two entries marked “undisclosed” (WittGen Biotechnologies on 2026-05-07 and BioGlyph on 2024-08-06). Disclosed amounts also include small prints like New Age Meats’ $2M (2021-02-12), while the date range spans 2020-12-01 (Newomics) through 2026-05-07 (WittGen Biotechnologies).
Most recent rounds
21 shownRelated listings
Frequently asked
What’s the biggest disclosed funding round in this Berkeley biotech list, and how does it compare to the rest?
Carmot Therapeutics’ $150M (2023-05-25) is the clear outlier on disclosed size, with the next-largest disclosed amounts at $125M (Caribou Biosciences on 2023-07-13) and $90M (Perfect Day on 2024-01-05). Multiple other disclosed rounds sit well below these figures, including $46M (SonALAsense on 2024-12-12) and $28M (Valitor on 2022-10-05).
Do the funding events cluster into a specific period rather than spreading evenly over 2020–2026?
Yes. Seven rounds land in a tight stretch from 2023-02-15 (Flightpath Biosciences) through 2023-10-18 (Actym Therapeutics), including $1M (Flightpath Biosciences on 2023-02-15), $10M (Pow.bio on 2023-10-04), and $26M (Actym Therapeutics on 2023-10-18). Outside that window, there are fewer entries despite the list spanning 2020-12-01 to 2026-05-07.
How often is stage unspecified, and do those entries skew toward larger or smaller disclosed amounts?
“Series Unknown” appears in 5 entries, such as Kyverna Therapeutics at $25M (2025-11-03) and SonALAsense at $46M (2024-12-12). Separately, 2 entries are “undisclosed” (WittGen Biotechnologies on 2026-05-07 and BioGlyph on 2024-08-06), while disclosed “Series Unknown” amounts include both mid-to-high ($46M, $25M) and low ($1M for Novel Farms on 2023-09-28).
Which stage labels dominate among disclosed rounds (vs. Series Unknown/undisclosed), based on the entries shown?
Among non-unknown labels, later-stage designations show up repeatedly: Series E includes Perfect Day ($90M on 2024-01-05) and Carmot Therapeutics ($150M on 2023-05-25). Earlier labeled rounds also recur, including Series A at Actym Therapeutics ($26M on 2023-10-18) and Pow.bio ($10M on 2023-10-04), plus multiple Seed rounds like MeliBio ($6M on 2022-03-17) and Fauna Bio ($9M on 2021-09-21).
Are there unusually small or large rounds besides the top outlier that might warrant closer review?
Yes. On the low end of disclosed amounts, several entries are $1M–$2M, including Novel Farms ($1M on 2023-09-28), Flightpath Biosciences ($1M on 2023-02-15), and New Age Meats ($2M on 2021-02-12). On the high end, a second tier is present at $125M (Caribou Biosciences on 2023-07-13) and $90M (Perfect Day on 2024-01-05), before the list drops toward amounts like $46M (SonALAsense on 2024-12-12).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.